Pharma Mar (PHMMF) Stock Price, News & Analysis

Company Overview

PharmaMar is a Spain-based biopharmaceutical company that specializes in the discovery and development of novel oncology therapies derived from marine organisms. Founded in 1986 as part of Grupo Zeltia, the company has pioneered the use of compounds extracted from deep-sea organisms to create synthetic analogs aimed at treating various forms of cancer. Its core expertise lies in marine biotechnology, medicinal chemistry and oncology-focused clinical development.

The company’s flagship product is Yondelis (trabectedin), an antitumor agent approved in the European Union for the treatment of soft tissue sarcoma and relapsed platinum-sensitive ovarian cancer. In collaboration with international partners, PharmaMar has also advanced lurbinectedin (Zepzelca) through clinical trials, securing FDA approval in the United States for the treatment of metastatic small cell lung cancer. Additional pipeline candidates include plitidepsin (Aplidin), currently under review for hematological malignancies and other oncology indications.

Headquartered in Madrid, PharmaMar maintains research facilities in Spain and operates through a network of licensing agreements and strategic partnerships across Europe, North America and Asia Pacific. The company’s subsidiaries, such as Genomica (molecular diagnostics) and Sylentis (RNA interference therapeutics), extend its capabilities into precision medicine and genomic technologies, reinforcing its integrated approach to cancer research and patient care.

Under the leadership of President and CEO José María Fernández Sousa-Faro, PharmaMar continues to expand its global footprint by advancing late-stage clinical programs and negotiating regional commercialization deals. The company’s ongoing commitment to marine-based drug discovery positions it as a distinctive player in the oncology landscape, with a focus on unmet medical needs and innovative therapeutic solutions.

Key Stats

• Today's Range: $90.90 to $90.90
• 50-Day Range: $79.49 to $106.48
• 52-Week Range: $77.41 to $110.40
• Volume: 102 shs
• Average Volume: 27 shs
• Market Capitalization: $1.64 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Buy

Pharma Mar Stock Analysis - MarketRank™

Pharma Mar scored higher than 37% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.1 / 5
• Analyst Rating: Buy

Consensus Rating

Pharma Mar has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 strong buy rating, 1 buy rating, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Pharma Mar has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Pharma Mar are expected to grow in the coming year, from ($1.06) to $1.39 per share.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of Pharma Mar has been sold short.

Short Interest Ratio / Days to Cover

Pharma Mar has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Pharma Mar has recently decreased by 99.27%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Pharma Mar does not currently pay a dividend.

Dividend Growth

Pharma Mar does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.35

News Sentiment

Pharma Mar has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Pharma Mar this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Pharma Mar insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.88% of the stock of Pharma Mar is held by insiders.

Percentage Held by Institutions

Pharma Mar has minimal institutional ownership at this time.

Company Calendar

• Today: 7/10/2026
• Next Earnings (Estimated): 7/29/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:PHMMF
• Previous Symbol: NASDAQ:PHMMF
• CIK: N/A
• Web: www.pharmamar.com
• Phone: (491) 846-6000
• Fax: 34-91-846-6001
• Employees: 509
• Year Founded: 1986

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.14
• Current Ratio: 3.02
• Quick Ratio: 2.44

Sales & Book Value

• Annual Sales: $250.42 million
• Price / Sales: 6.53
• Cash Flow: $0.40 per share
• Price / Cash Flow: 227.76
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 18,000,000
• Free Float: 17,662,000
• Market Cap: $1.64 billion
• Optionable: Not Optionable
• Beta: 0.70